Ergoteles LLC Has $78,000 Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)

Ergoteles LLC lessened its holdings in shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) by 72.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 24,725 shares of the company’s stock after selling 65,675 shares during the period. Ergoteles LLC owned 0.06% of Immunic worth $78,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of IMUX. Point72 Asset Management L.P. lifted its position in Immunic by 82.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,325,000 shares of the company’s stock valued at $4,598,000 after acquiring an additional 600,000 shares in the last quarter. BlackRock Inc. boosted its position in shares of Immunic by 0.9% during the 1st quarter. BlackRock Inc. now owns 1,314,484 shares of the company’s stock worth $14,853,000 after acquiring an additional 11,708 shares in the last quarter. Vanguard Group Inc. lifted its stake in Immunic by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 956,697 shares of the company’s stock valued at $10,811,000 after purchasing an additional 54,867 shares during the last quarter. Gratus Capital LLC bought a new position in Immunic in the 3rd quarter valued at approximately $2,380,000. Finally, Verition Fund Management LLC raised its stake in shares of Immunic by 331.5% during the second quarter. Verition Fund Management LLC now owns 609,765 shares of the company’s stock valued at $2,116,000 after acquiring an additional 468,446 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Immunic Price Performance

NASDAQ IMUX opened at $2.17 on Thursday. The company’s 50 day moving average is $1.91 and its 200-day moving average is $2.73. Immunic, Inc. has a 12-month low of $1.11 and a 12-month high of $12.64.

Analysts Set New Price Targets

A number of equities research analysts have commented on IMUX shares. Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Tuesday, January 31st. StockNews.com raised shares of Immunic to a “sell” rating in a research report on Tuesday, February 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.00.

About Immunic

(Get Rating)

Immunic, Inc is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856.